THIS STUDY IS UNDERTAKEN TO ASSESS THE EFFECT OF PRETREATMENT WITH ROCURONIUM BROMIDE IN PREVENTING ETOMIDATE INDUCED MYOCLONUS DURING ANAESTHETIC INDUCTION .AS ETOMIDATE IS A NOVEL ANAESTHESTHETIC AGENT WITH MYOCLONUS AS THE ONLY LIMITING FACTOR

A CLINICAL STUDY TO ASSESS THE EFFECT OF PRETREATMENT WITH ROCURONIUM BROMIDE IN PREVENTING ETOMIDATE INDUCED MYOCLONUS DURING ANAESTHETIC INDUCTION .

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/02/023506

Enrollment

Registered

2020-02-21

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K819- Cholecystitis, unspecified

Interventions

Intervention1: Rocuronium pretreatment in prevention of etomidate induced myoclonus: 0.06 mg of rocuronium is given before induction with etomidate

Eligibility

Inclusion criteria

Inclusion criteria: ASA physical status 1 and 2 . Patients who gave written informed consent.

Exclusion criteria

Exclusion criteria: Patients not willing to participate in the study, Patients with cardiovascular disease,respiratory disease,hepatic , renal and adrenal disease and epilepsy. Pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
MyoclonusTimepoint: At 1-3 min after etomidate injection	—

Secondary

Measure	Time frame
Pain on injectionTimepoint: at the time of etomidate injection	—

Countries

India

Contacts

Public ContactDr Nethra S S

Bangalore medical college and research institute

nethra.surhonne@gmail.com9448171403

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026